Pharmacovigilance is an increasingly vital function for pharma manufacturers, and this function must be maintained throughout the entirety of the drug lifecycle. The advent of stringent Risk Management Plans (RMPs) combined with new and complex European regulations require pharma and biotech companies to invest a greater focus and increased resources into drug safety monitoring. The cry for greater transparency from the media means pharmacovigilance is now being placed firmly in the public spotlight. But how can this transparency be achieved and how are these regulations evolving?

The 4th annual Pharmacovigilance and Risk Management conference will bring together key industry experts to provide answers to these and other topical questions. From the difficulties with RMPs and the challenges of signal detection to achieving effective communication with health authorities, this conference will provide insight in how to solve the critical issues facing the industry today.

Password: